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cense.Abstract Purpose: To investigate the role of stereotactic radio surgery (SRS) and hypo-
fractionated stereotactic radiotherapy (SRT) in treatment of benign intracranial meningioma.
Patients and methods: Between 2003 and 2010, 32 patients with a median age of 44 years (range
21–67 years) were treated with SRS (n= 19), and hypo-fractionated SRT (n= 13) for intracranial
meningioma. Fourteen patients underwent SRS or SRT as their primary treatment, while 18
patients underwent post operative SRS or SRT (PORT). Cumulative progression free survival,
overall cumulative survival, toxicity and symptomatology were evaluated.
Results: The median follow up period was 39 months (range 6–72 months). The 5 year overall sur-
vival and progression free survival were 90 ± 5% and 94 ± 4% after SRT or SRS respectively.
Symptoms were improved or stable in 94% of patients. Acute toxicity was mild, and was seen in
41% of patients. Clinically signiﬁcant late morbidity or new cranial nerve palsies did not occur.
Conclusion: Stereotactic radio surgery (SRS) and hypo-fractionated stereotactic radiotherapy
(SRT) are effective and safe treatment modality for local control of meningioma with low risk of sig-
niﬁcant late toxicity. In case of large tumor size and adjacent critical structures, hypo-fractionated
SRT is highly recommended.
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lsevierIntroduction
Meningioma is the most common primary brain tumors,
accounting for approximately 14–20% of non-glial brain tu-
mors. Although they are usually benign, they can be associated
with signiﬁcant morbidity when encroaching on sensitive struc-
tures such as cranial nerves [1,2].
Surgery remains the mainstay of treatment with excellent lo-
cal control, but may be limited by the size and site of tumor. The
risk of cranial nerve palsies and other morbidities remains sig-
niﬁcant despite recent advances in microsurgical techniques [3].
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has the potential to improve outcome and to increase survival
rates [4,5]. In order to reduce radiation induced side effects
and to increase local control, sophisticated treatment planning
like stereotactic fractionated radiotherapy (SRT), stereotactic
radiosurgery (SRS) and intensity modulated radiotherapy is
recommended [6–8]. These techniques have enabled improved
conformation of the treatment volume to the target, which is
often small, of complex shape, and close to critical structures
such as the brain stem, pituitary, and optic chiasma.
The aim of this work is to report our experience with stereo-
tactic radiosurgery (SRS) and hypo-fractionated stereotactic
radiotherapy (SRT) in the treatment of benign meningiomas
with respect to local control, radiation-induced side effects,
and overall survival.
Patients and methods
This is a retrospective study of 32 patients with intracranial
benign meningioma who were treated with stereotactic radio-
surgery (SRS) (19 patients), and hypo-fractionated stereotactic
radiotherapy (SRT) (13 patients) during the period from 2003 to
2010 at the National Cancer Institute, Cairo university, Egypt.
All patients were evaluated before treatment by MRI. Max-
imal tumor diameter, tumor volume and distance to critical
neural structures (optic pathway or brain stem) were assessed
in all cases. Tumor with radiological well deﬁned lesion, small
volume (approximately less than 20 cc) and away from critical
structures were candidates for stereotactic radiosurgery. Le-
sions with large volume and/or involving (or adjacent to) crit-
ical structures (brain stem and optic chiasma) were treated
with hypo-fractionated SRT. The Karnofsky performance sta-
tus (KPS) was recorded at the beginning of treatment and dur-
ing follow up.
Treatment methods
Patient immobilization was achieved using Brown–Roberts–
Wells (BRW) stereotactic localization frame in SRS, and Gill–
Thomas–Cosmin (GTC) frame in hypo-fractionated SRT with
repositioning accuracy <2 mm according to published data
[9,10].
Treatment planning was performed on a three-dimensional
CT data generated from continuous 2-mm CT scans. MRI
scans were obtained in the treatment position. CT and MRI
fusion was carried out using the three-dimensional planning
system Radionics (X-Knife version 2). After stereotactic image
fusion, the target volume and organs at risk, such as the eyes,
optic nerves, chiasma and brain stem, were delineated on each
slice of the three dimensional data. The planning target volume
included the macroscopic tumor visible on MRI with a safety
margin 2 mm in hypo-fractionated stereotactic radiotherapy
(SRT) and no margin in stereotactic radiosurgery (SRS). Opti-
mal dose distribution within the target volume and minimal
dose to normal brain and critical structures were achieved with
ﬁxed non coplanar beams using either multi leaf collimator
(leaf width 2 mm at the isocenter) or cones with different sizes.
Treatment was delivered with 6 MV linear accelerator. The
tumor margin dose was 11-12 GY in SRS patients and
2520 cGY in 6 fractions in hypo-fractionated SRT (equivalent
to 50 GY/25 F/calculated for a/b= 2). Evaluation of treat-
ment planning was carried out by isodose line distribution,dose volume histogram and target dose conformity. The pre-
scription isodose volume to target volume ratio (PITV) is used
by the Radiation Therapy Oncology Group (RTOG) to de-
scribe the conformity of prescription isodose line to the target
volume. An exemplary treatment plan with beam’s eye view is
shown in Fig. 1.
Follow up included radiologic (CT/MRI), clinical and neu-
rologic examinations at 3 and 6 months after radiotherapy,
then once a year. Radiologic tumor response was assessed after
exact image fusion and measured volumetrically by use of
fused thin slice MRI data sets. Tumor volume shrinkage was
analyzed three dimensionally and quantitatively by use of
planning system. If this procedure was not available, the tumor
diameters were compared in 3 dimensions. Ophthalmologic
examination and visual ﬁeld perimetry in sellar and parasellar
meningioma was performed after 6 months and then annually
after radiotherapy. Side effects were assessed as either acute or
late phenomena according to the Radiation Therapy Oncology
Group (RTOG) morbidity criteria [11]. A toxic effect was con-
sidered to be acute if it occurred within the ﬁrst 90 days after
start of treatment, and was considered late if it occurred after
90 days from the start of treatment.
Overall survival was calculated from the date of starting
radiotherapy until the date of death or the date of last follow
up, and progression free survival was calculated from the date
of starting radiotherapy until the date of ﬁrst progression or
the date of last follow up.
Statistical methods
Statistical analysis was done using SPSS win statistical pack-
age version 15, estimates of the survival rates (cumulative over-
all survival and progression free survival) were calculated using
the Kaplan–Meier product-limit method and presented as
cumulative survival and standard error at the end of follow
up period.
Results
They were 25 female patients and 7 males. The median age was
44 years (range 21–67 years). Fourteen patients underwent
SRS or SRT as their primary treatment while 18 patients
underwent post operative SRS or SRT. The histological or
radiological diagnosis of benign meningioma was conﬁrmed
in all patients. Table 1 shows the patients characteristics.
Median followupperiodwas 39 months (range 6–72 months).
Symptomsof increased intracranial pressure (headache, vomiting
andblurringof vision)were themost commonly encountered seen
in 75% (24/32) of the patients, followed by neurological deﬁcits
(motor weakness, impaired sensation and nerve affection)
detected in 63% (20/32) of the patients. Convulsion was encoun-
tered in 22% (7/32 patients), while hormone deﬁcit was seen in
6% (2/32) of the patients. All patients were (KPS) more than
70. In 31% (10/32) of the patients, preexisting neurologic symp-
toms improved, 63% (20/32) remained unchanged and 6% (two
patients) get worse.
Table 2 shows the distribution of 32 patients according to
the site of the lesions. Sellar and parasellar lesions were the
most common (31%) followed by lobar lesions (28%). The
total number of all treated lesions was 36 lesions.
The tumor volume ranged from 1 to 39.7 cc, with a median
of 8.5 cc. Dose delivery was normalized to isodose line ranged
Table 1 Patient’s characteristics.
Age (year)
Median 44
Range 21–67
Sex (No.%)
Female 25 (78%)
Males 7 (22%)
Follow up (months)
Median 39
Range 6–72
Tumor volume (cc)
Median 9.2
Range 1.8–39.7
Treatment groups (No.% of patients)
SRS 19 (59%)
Hypo-fractionated SRT: 13 (41%)
Types of treatment (No.% of patients)
Primary 14 (44%)
PORT 18 (56%)
Figure 1 Exemplary treatment plan. (a) Observer’s view of tumor and organ at risk. (b) Transverse view. (c) Coronal view. (d) Sagittal
view.
Table 2 Distribution of 32 patients according to the site of the
lesions.
Site Frequency (n= 32) Percentage
Sellar & parasellar 10 31
Lobar 9 28
Cavernous sinus 5 16
Skull base 8 25
Stereotactic radiosurgery and radiotherapy in benign intracranial meningioma 91from 55% to 94%, the median being 85% isodose line. The
volume of lesion covered with the prescribed dose ranged from
86% to 99.5%, the median being 94%. The number of nonco-
planar arcs ranged from 4 to17 arcs, the median being 6 arcs.
All patients were treated with PITV ratio less than 2 (Fig. 2).Stable disease based on MRI was seen in 20/32 (63%)
patients, while 10/32 (31%) patients had a reduction of tumor
volume of >50% and 2/32 (6%) patient had a progression of
tumor volume of >25% during follow up period.
Two patients died 6 and 7 months after end of treatment
due to cardiac failure while one patient died from disease pro-
gression 32 months after end of treatment. The cumulative
overall survival rate for the whole group was 90 ± 5% at
5 years, (Fig. 3). Overall tumor growth control at the last
follow up was observed in 30 patients. Cumulative progression
free survival (PFS) at 5 years was 94 ± 4%, (Fig. 4). Two
patients exhibited tumor progression; both of them had para-
sellar meningioma.
Acute toxicity was mild and consisted of mild headache,
transient tinnitus or general weakness in 8/32 (25%) patients.
Short term course of corticosteroids therapy (<3 months)
Figure 2 The distribution of brain lesions as regards the PITV
ratio.
Figure 3 Cumulative overall survival of 32 patients with benign
intracranial meningioma.
Figure 4 Cumulative progression free survival of 32 patients
with benign intracranial meningioma.
92 E. Eldebawy et al.was given to 3/32 (9.3%) patients. Visual ﬁeld deterioration was
seen in 2/32 (6.2%) patients, one of them was due to disease
progression. No patient developed hypothalamic–pituitary
dysfunction. No sign of increased intracranial pressure due to
post radiation therapy oedema was detected in our patients.
No late toxicity was detected within the follow up period.Discussion
An increasing number of reports concerning SRS and SRT as
an adjuvant treatment or as an alternative therapy to aggressive
microsurgery have been published. SRT given after incomplete
resection of primary or recurrent meningioma or as ﬁrst line
treatment has been shown to improve tumor control compared
with outcomes in patients treated by surgery alone [12–17].
More recently, several studies have reported encouraging
results on SRS treatment for benign meningioma. Despite
the objections raised after the publications of preliminary
results of this technique, long term evaluation of SRS in
meningioma treatment has demonstrated an improved tumor
control whether used as ﬁrst line or post resection adjuvant
treatment [18–20].
The 5 year PFS rate for 32 patients with benign meningi-
oma treated by SRS and SRT in our department was 94%.
These data are nearly comparable with other reports [21–25]:
Selch et al. reported a 3-year progression free survival of
97.4% in 45 patients treated for benign meningiomas with
fractionated stereotactic radiotherapy [21]. Jalali et al. with a
median follow up of 21 months has reported no recurrences
in 41 patients treated with SRT [22]. The largest study to date
was introduced by Debus et al. A total number of 189 patients
treated with fractionated stereotactic radiotherapy with a med-
ian follow up of 35 months have been followed; local control
was excellent, with only 3 patients recurring [23].
Single fraction stereotactic radiosurgery has also been used
extensively to treat skull base meningiomas with similar high
levels of local control. Lee et al. reported a series of 159
patients with cavernous sinus meningiomas treated with gam-
ma knife radiosurgery showing local control of 93% with a
median follow up of 35 months [24]. Shafron et al. treated 70
benign meningiomas with a mean follow up of 23 months
showing a 100% control rate [25].
Our results are better than the results achieved in microsur-
gical series with available follow up [26–28]. In the two princi-
pal microsurgical series, the PFS rate ranged from 61.5% to
80.7% with a mean follow up inferior to 4 year [26,27].
On the basis of different deﬁnitions and preconditions, the
data for radiologic tumor response is very heterogeneous.
Tumor volume shrinkage was published between 13% and
61% [29–32]. If not measured volumetrically (by use of fused
thin slice MRI data sets), the interpretation of these results
appears to be very difﬁcult. Most of the authors deﬁne regres-
sion as 2 mm shrinkage in tumor diameter, but to have MRI
images with exactly the same slice angulations available is rare,
even though they are needed for exact comparison [33,34]. In
our patient group, in respect to our deﬁnition of tumor volume
shrinkage/enlargement, tumor shrinkage (reduction of tumor
volume of >50%) was observed in 31% of patients.
In comparing our study to those of other authors, we ob-
served an unchanged (63%) and improved (31%) clinical status.
Only 2 of 32 patients (6%) showedworsening conditions.Higher
[33,34] and lower [25,31,32] worsening rates were published.
Conclusion
SRS and SRT are effective and safe treatment modality for
local control of meningioma with low risk of signiﬁcant acute
and late toxicity. In case of large tumor size and adjacent
critical structures SRT is highly recommended.
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